Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly.

Trial Profile

Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly
  • Focus Registrational; Therapeutic Use
  • Sponsors Endo Pharmaceuticals Solutions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Sep 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Aug 2013 Primary endpoint 'Growth-hormone-levels' has not been met according to results published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top